Abstract:Aim: To construct a vector expressing through target gene given by human telomerase reserve transcriptase (hTERT) promoter with pLHCX as vector and realize target expression. Methods: Experiments were performed at the Key Laboratory of Molecular Medicine from September 2005 to May 2006. 1 The phTERT-luc plasmid containing 319 bp hTERT core promoter was presented by Dr. Zheng from Military Academy of Science; Retrovirus vector pLHCX was presented by Professor Zhu from Zhejiang University; The plasmid pCMV-Neo-BamH-wtp53 containing 1.8 kb wtp53 gene was presented by Professor Zhu from Second Military Medical University of Chinese PLA; Enhanced green fluorescent protein report plasmid pEGFP-N2 and pEGFP-C1 were kept in this laboratory; human carcinoma of large intestine cell strain SW620 and HT-29, human cervical carcinoma cell strain Hela, human lung carcinoma cell strain A549, and human lung embryo fibroblast MRC-5 were kept in this laboratory. 2 The plasmid pLHCX-hTERT-EGFP expressing EGFP driven by hTERT promoter and the plasmid pLHCX-hTERT-wtp53 expressing wtp53 also driven by hTERT promoter were constructed through directional cloning. The plasmid pLHCX-hTERT-EGFP and the plasmid pLHCX-CMV-EGFP were used for the transfection of human carcinoma of large intestine cell strain SW620 and HT-29, human cervical carcinoma cell strain Hela, human lung carcinoma cell strain A549, and human lung embryo fibroblast MRC-5. 3 The flow cytometer was used to analyze the transfection efficiency of pLHCX-hTERT-EGFP so as to declare the HTERT promoter specific expression in tumor cells. The human colon cancer cell line SW620, which the p53 gene is mutation, were infected with the plasmid pLHCX-hTERT-wtp53 and p53 mRNA, p53 protein were demonstrated with RT-PCR and Western blot. The normal human embryo lung fibroblast cell strain MRC-5 and the human colon cancer cell line SW620 and HT-29 were treated with the plasmid pLHCX-hTERT-wtps3, the propagate inhibition and apoptosis of cells were detected by MTT' and FCM, respectively. Results: 1 The plasmids pLHCX-hTERT-EGFP and pLHCX-hTERT-wtp53 were successfully constructed, which were confirmed by restriction endonuclease and sequencing. Green fluorescent protein expression was observed by pLHCX-hTERT-EGFP transfection SW620. The sequencing verified that complete wtp53 fragment was found. 2 Flow cytometry declared that enhanced green fluorescent protein expression was significantly higher in the SW620, Hela and A549 than the MRC-5 after pLHCX-hTERT-EGFP treatment (P < 0.05), but no significant difference was found in positive and negative cells above mentioned (P > 0.05). 3 The expression of wtp53 mRNA and the protein were demonstrated by RT-PCR and Western blot, respectively. 4 MTT showed that recombinant plasmid had significant inhibition on carcinoma of large intestine with positive telomerase, but had no significant effects on MRC-5 cells with negative telomerase (P < 0.05). 5 Flow cytometry showed that the apoptosis of carcinoma of large intestine with positive telomerase was significantly higher than the MRC-5 cells with negative telomerase induced by recombinant plasmid (P < 0.05). Conclusion: The retroviral vector pLHCX-hTERT-EGFP can express in tumor cells specifically and the retroviral vector pLHCX-hTERT-wtp53 can affect carcinoma of large intestine with positive telomerase specifically.

Preparation of Recombinant Retrovirus Containing Wild Type P53cdna

The Study of P53 Gene Therapy for Ovarian Cancer--construction of Recombinant Mammalian Expressing Vector for Human Wild-Type P53 Gene

Construction of retroviral vector expressing wild type p53 gene driven by hTERT promoter firstly by retrovirus only infecting dividing cells

Construction and Identification of Recombinant Adeno-Associated Virus Vector Mediating the Expression of the Derepressing P73 Peptide-P53 (N37)

Construction and Identification of Recombinant Adenovirus Vector Harboring Fusion Gene NT4-p53 (N15)-Ant

The Effects of Recombinant Adenovirus-Mediated Wild Type p53 cDNA on Human Colorectal Cancer Cell Lines with Different p53 Status

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

Establishment and Identification a New PC12 Cell Line Which Contains Inactivated Wild-Type P53 Protein

Antitumor Effected by Retroviral Expressing Wtp53 Gene Driven by Htert Promoter

Construction and Identification of Vectors Encoding Both Wide Type P53 Protein and Sirna-Vegf on PC-3 Cells

[Preparation of the High-Titer Retroviral Viruses for Transducting PDGF-A Gene].

Construction and Identification of the Recombinant Adenovirus Vector Targeting EBV-positive Lymphoma

Activities of Wildtype and Mutant P53 in Suppression of Homologous Recombination As Measured by a Retroviral Vector System

Knockdown of Human P53 Gene Expression in 293-T Cells by Retroviral Vector-Mediated Short Hairpin Rna

[Expression, Purification and Transduction of Tat-p53 Fusion Protein].

Study on Anti-Glioma Effect of Recombinant Adenovirus Mediated HSV-TK/ACV System Enhanced by wt- p53 Gene in vitro

Expression,purification and Transduction of PTD-p53 Fusion Protein to Hepatocellular Carcinoma Cell

Clinical Utility of Recombinant Adenoviral Human P53 Gene Therapy: Current Perspectives

An Experimental Study on Recombinant Adenovirus P53 Transfected in Oral Dysplastic Epithelial Cells

The Construction of a Hepatoma-Specific Adeno-Associated Virus Vectorcarrying P53 Gene

Recombinant Newcastle Disease Virus Expressing P53 Demonstrates Promising Antitumor Efficiency in Hepatoma Model.